Bristol Myers Squibb $4.5 billion notes offering
The investment-grade offering comprised four tranches
Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with an SEC-registered public debt offering by Bristol Myers Squibb Company, consisting of $1 billion of 5.750% notes due 2031, $1 billion of 5.900% notes due 2033, $1.25 billion of 6.250% notes due 2053 and $1.25 billion of 6.400% notes due 2063. Bristol Myers Squibb Company intends to use the proceeds of the offering for general corporate purposes, including, but not limited to, the financing of the proposed acquisition of Mirati Therapeutics, Inc. and related fees and expenses.
Bristol Myers Squibb Company is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
The Davis Polk capital markets team included partner Richard D. Truesdell Jr., counsel Jennifer Ying Lan and Joseph S. Payne and associate Yi Wang. The tax team included partner William A. Curran and associate Yueyu Yang. Counsel Michael Comstock provided environmental advice. The intellectual property team included partner David R. Bauer and associates Alison T. Chin and Lauren Nathan. All members of the Davis Polk team are based in the New York office.